Navigation Links
Moderate Use of Analgesics - Not Associated With Kidney Dysfunction

According to a new study, occasional use of aspirin, acetaminophen, or other pain relievers for everyday aches and pains is not associated with kidney dysfunction among healthy men.

As analgesic use is so common, even small increases in the relative risk of renal dysfunction could have a significant impact on rates of renal disease.

Some earlier studies have suggested that regular use of popular pain killers such as aspirin, acetaminophen, and other nonsteroidal anti-inflammatory drugs(NSAIDs) may increase the risk of chronic kidney problems in healthy patients.

Researches at Women's hospital in Boston analyzed the use of these pain relievers among 11,032 men with no history of kidney problems. They compared analgesic use to measured creatitine levels and creatitine clearance from blood samples provided by the men. A total of 450 men had elevated creatinine levels and 1258 men had reduced creatinine clearance.

They found no significant associations between the use of pain killers and either elevated creatinine levels or reduced creatinine clearance. Thus, occasional or moderate use of pain relievers or NSAIDs is not associated with kidney dysfunction.
'"/>




Page: 1

Related medicine news :

1. Moderate alcohol consumption protects against dementia
2. Moderate Exercise may not help prevent Heart Disease
3. The Benefits Of A Diet Consisting Of Moderate Amounts Of Fat
4. Moderate drinking can be good for the kidneys
5. Enjoy Moderate Exercise and Keep Your Heart Fit
6. Even Moderate Drinking Is Not Good For The Heart
7. Moderate Drinkers Found to Escape Obesity and Related Problems
8. Moderate Exercise Is Good For The Heart: Study
9. Moderate Drinking Can Help Cut Diabetes Risk In Middle-Aged Women
10. Moderate Drinking Does Not Guard Against Heart Disease
11. Children Benefited By Moderate Maternal Stress?
Post Your Comments:
(Date:7/25/2008)... This donation will be used to facilitate...ices for children , Haupp...ivci.com ), a leading integrator of enterprise co...deo conferencing, telepresence, audio visual integ...ed today that it has donated video conferencing eq...
(Date:7/24/2008)...EM, N.C. Researchers at Wake Forest University B...ng clinical belief that the hepatitis C virus slow... itself after HIV patients are treated with a comb...atitis C (HCV) infection is more serious in HIV-in...rding to the Centers for Disease Control. Intraven...
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Speaker Nancy P...g in support of the Tom Lantos,and Henry J. Hyde G...nd,Malaria Reauthorization Act of 2008. The bill, ...e this evening by a vote of 303 to 115 and will no...Today the House took an historic vote to pass land...
(Date:7/24/2008)...olo., July 24 /PRNewswire/ -- An Arapahoe County D...ic company what will likely,amount to more than $1...tween the minority shareholders of Inverness-based...-based private company PR Pharmaceuticals, Inc.,Th...dent, Steven Howe, and,CEO, Dr. Patrick Bols, brea...
Breaking Medicine News(10 mins):Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2Health News:Jury Award to Englewood Company to Total More Than $1 Million for Breach of Fiduciary Duties in Shareholder Class Action Case 2
...er Christina Aguilera is fuelling her pregnancy ru.... The 26-year-old is reportedly pregnant with hub...following her visit to maternity doctor recently. ...s also denied confirming the reports. 'I cannot c...
...bureaucratic reaction, the Californian authorities...ital at the centre of national outrage over a wom...cy room. The Martin Luther King Jr.-Harbor hospi...unty department of Health Services, is located n...
...some positive effects as well, for researchers hav...oid arthritis . The study was conducted by a team... Stockholm, Sweden. As part of the study, researc...tion-based case-control study of incident cases of...
...the University of Pittsburgh School of Medicine ha...ave significant implications for the treatment of ...om muscle-derived stem cells (MDSCs) and a biodegr... extensive remodelling, and remain free of blockag...
Other Medicine News:Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 2Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 3Health News:Government Mulls Closure of Hospital Where a Woman Died Unattended in ER 4Health News:Alcohol Consumption may Help to Protect Against Rheumatoid Arthritis 2Health News:Scientists Develop Artificial Blood Vessels for Vascular Grafts in Mice 2
(Date:7/22/2008)...cuss Development Plan Completed Successfully, DUB...arin Corporation,plc (NASDAQ: AMRN ) today announ...t the U.S. Food and Drug Administration (FDA) to d...he treatment of,hypertriglyceridemia. Following th...e 3 with AMR101 in hypertriglyceridemia., Dr. Dec...
(Date:7/22/2008)...l Stress the Importance to Patients of Passing a ...ay, RICHMOND, Va., July 22 /PRNewswire-FirstCall/...ollow-on biologics and biopharmaceuticals, today,a..., will present at a,Congressional briefing on Frid...d for establishing an approval pathway for follow-...
(Date:7/22/2008)...ative Laser Lipolysis Technology in the European ...ass., July 22 /- Cynosure, ...ufacturer of a broad array of,light-based aestheti...Mark,for Smartlipo MPX(TM), the company,s high-pow...uefy fat and tighten skin through collagen,remodel...
(Date:7/21/2008)...s on use of Zevalin as consolidation therapy after...ents with follicular ...l/ -- Cell Therapeutics, Inc.,(CTI) (Nasdaq and MT...duled,a meeting with the U.S. Food and Drug Admini...lity of filing a supplemental Biologics License,Ap...
Breaking Medicine Technology:Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation 2Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation 3CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 2CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 3CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R) 4Halozyme Therapeutics Presents Pre Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association 1791 1Halozyme Therapeutics Presents Pre Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association 1791 2Halozyme Therapeutics Presents Pre Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association 1791 3Halozyme Therapeutics Presents Pre Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association 1791 4New HPV Vaccine Promising in Mice 16809 1New HPV Vaccine Promising in Mice 16809 2New HPV Vaccine Promising in Mice 16809 3Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 1Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 2Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 3Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 4Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 5Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 6Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 7Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 8Forest Laboratories Inc Reports Fiscal Year 2008 Fourth Quarter Reported EPS of 240 55 Including 240 35 Per Share Charge for Licensing Payment 16804 9AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4593 1AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4593 2AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4593 3AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4593 4
... 5, 2007 - MIV Therapeutics Inc.,(OTCBB:MIVT) (FWB...ompatible coatings and advanced drug delivery syst...e medical devices, today,announced that a recent C... Biosync Scientific,s certified bare metal stent p...mpany,s polymer-free drug,delivery system met crit...
...RNewswire/ -- Nereus,Pharmaceuticals, Inc., a pion...microbial sources, and its collaborators will pres...ng its cancer drug,candidates at the American Asso...Angeles April 14-18. Four posters and two,minisymp...tumor,activity in several tumor models for three N...
Other Medicine Technology:MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 2MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 3MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 4Nereus Pharmaceuticals to Present Data at the American Association,for Cancer Research 2007 Annual Meeting 2Nereus Pharmaceuticals to Present Data at the American Association,for Cancer Research 2007 Annual Meeting 3Nereus Pharmaceuticals to Present Data at the American Association,for Cancer Research 2007 Annual Meeting 4Nereus Pharmaceuticals to Present Data at the American Association,for Cancer Research 2007 Annual Meeting 5
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish.
Straight shafts with teeth and 6 mm crisscross serrated tying surfaces. Serrated handle with polished finish.
Straight shafts with 1 x 2 teeth. Wide serrated handle with polished finish.
Serrated, 10 mm tips angled 90 degrees. Serrated cross action handle with polished finish.
Medicine Products: